10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics won a jury verdict finding Parse Biosciences willfully infringed Scale Biosciences' patents, while Parse’s invalidity challenge was rejected. The ruling strengthens TXG’s intellectual-property position, but damages, appeals and the precise commercial reach of the patents still determine the financial impact.
What happened
10x Genomics won a jury verdict finding Parse Biosciences willfully infringed Scale Biosciences' patents, while Parse’s invalidity challenge was rejected.
The read · Aug 28
The patent verdict moves the legal and competitive risk in TXG’s favor, but the financial read remains limited until damages and remedies are disclosed.
Wrong if
The read weakens if Parse overturns or narrows the verdict, or if the final remedy produces little or no economic benefit for TXG.
CoverageFirst reported by PR Newswire at 2:38 PM ET · the only report so farHow this is decided →
The chart · TXGTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story2 min read
The verdict announced Aug. 28 found that Parse Biosciences willfully infringed patents owned by Scale Biosciences, according to 10x Genomics’ PR Newswire release. The jury also rejected Parse’s challenge that the patents were invalid. The announcement identifies 10x as the life-science technology company focused on accelerating scientific research and advancing human health, but the supplied report does not specify a damages amount or the exact remedies awarded.
The case adds a legal development to 10x’s operating story, which otherwise shows a business with $642.8 million of FY 2025 revenue, up 5.2% year over year. Its reported gross margin was 69.1%, while net margin was -6.8% and diluted EPS was $-0.35. Those figures frame the importance of any patent-related economic benefit: the company is generating substantial revenue but remains unprofitable on the supplied numbers.
The named companies connect through the intellectual-property dispute. 10x Genomics is the publicly traded company in the release and is the ticker in play; Scale Biosciences is identified as the patent owner; and Parse Biosciences is the defendant found to have infringed. The concrete mechanism for TXG is potential protection of technologies or market positions covered by the patents, although the supplied material does not establish that the verdict directly awards revenue to 10x or describe any licensing arrangement.
The legal outcome is not necessarily the end of the dispute. Parse could challenge the verdict or seek to limit its effect, and the release as provided does not state the damages, injunction terms, appeal status or products implicated. It also does not establish how much of 10x’s business depends on the patents, so the operating contribution cannot be quantified from the available information.
The next facts to watch are the court’s damages and remedy decisions, any post-trial motions or appeal, and whether the parties disclose a settlement or licensing outcome. For 10x, subsequent company filings and operating results should show whether the verdict changes revenue, costs or competitive conditions. The next earnings date is not provided in the supplied data, so no dated earnings catalyst can be assigned here.
The read, in fullWhy it matters
The immediate benefit is stronger intellectual-property protection for TXG, but the supplied report does not disclose damages, an injunction or a licensing outcome. With TXG still reporting $642.8M of revenue, 5.2% YoY growth and a -6.8% net margin, the verdict’s earnings relevance cannot be sized until the court and the parties clarify its economic effect.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
Into damages and remedy disclosures. Follow to be told when one lands.
▲ The case it holds
The strongest bull hook is a willful-infringement finding paired with rejection of Parse’s invalidity challenge, potentially strengthening TXG’s ability to protect its commercial position.
▼ The case it breaks
The bear case is concrete but currently limited: no damages, injunction, licensing terms or direct TXG revenue award are provided, leaving the verdict’s financial value unquantified.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
PR NEWSWIRE / FILE